Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study) - Wikidata - wikimedia - TriplyDB

Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)

Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)

http://www.wikidata.org/entity/Q35005146

about

Barriers to a cure for HIV in women Preventing HIV infection: pre-exposure and postexposure prophylaxis Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Current perspectives in HIV post-exposure prophylaxis.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques The use of preexposure treatments for HIV prophylaxis Pharmacokinetics of antiretrovirals in mucosal tissue Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Antiretroviral bioanalysis methods of tissues and body biofluids.Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.Role of raltegravir in HIV-1 management.Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.

P2860

Q26768632-25EDAAE6-2B84-4742-B63C-99A8FD37841A Q26828445-24EC5AC9-8636-487E-BED9-A8E81EB33516 Q28081272-606106DF-4462-4B53-944D-3FA18C95F6F5 Q30431343-8D1ED403-134E-4344-926B-778E384A39EB Q33686465-0F0652C4-EB06-48CA-954D-1A7955B41738 Q33798045-BBA2356D-B58C-452C-A1C7-46186A16CE97 Q33888718-C36B2711-EBAD-42FB-867C-88F52CDAC5D7 Q34434815-E882D149-AD7D-41D0-94A7-A42A0E817E39 Q35432739-5ADD749B-E96E-4B6E-A122-D868523054C0 Q35760180-DDBF0E05-E10C-4A14-892B-12A9446B159C Q35838594-9C042602-268C-42C9-B26F-48B7F3C22188 Q36078470-B919450D-B2BD-46F8-8B9E-F05E38D590C1 Q36086387-8510F5DD-D47D-44B0-84D9-58062B716DFA Q36442232-79C60905-1DDF-49E8-B47A-587F95D25A31 Q36887876-32F9E23D-AA95-48D2-A2F9-F8CC9DA25E49 Q36901505-F740EFAC-82E6-427E-8A78-C4CDD5750D4A Q37332868-C861C540-87D1-4070-AF2D-B59CC414031F Q37592039-1BF86CF0-FDD8-48F3-AEEB-B649793E9DA5 Q38002011-C1830621-D88A-4D6E-AB72-9979E722A7AC Q38527537-B873CE8B-93A1-4BFD-9A0A-2F28A35DD8AC Q40103140-2D82F004-73BB-45A9-9245-CFA156CA12A4 Q47624840-D03844F0-D672-4463-96A6-66A0BDA13CE4

P2860

Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)

http://www.wikidata.org/entity/Q35005146

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Raltegravir concentrations in ...... aining regimen (DIVA 01 study)

@ast

Raltegravir concentrations in ...... aining regimen (DIVA 01 study)

@en

type

label

Raltegravir concentrations in ...... aining regimen (DIVA 01 study)

@ast

Raltegravir concentrations in ...... aining regimen (DIVA 01 study)

@en

prefLabel

Raltegravir concentrations in ...... aining regimen (DIVA 01 study)

@ast

Raltegravir concentrations in ...... aining regimen (DIVA 01 study)

@en

P1433

Q35005146-FA1C980B-4A07-422E-A704-422B1B75681D

P1476

Q35005146-19D97CC3-E81E-4450-BAE9-2E58177CFBB2

P2093

Q35005146-05CE9C57-8C00-489E-9776-CC7E5F382AB0

Q35005146-0819D2AB-CA94-431D-97C4-D44EB7860789

Q35005146-466D6F3D-C6C9-48A8-9CB2-FD884E792F99

Q35005146-7A2A279B-4CDD-4B6D-9248-DD2B823B957F

Q35005146-832A741B-3F22-4AC6-B83E-53B3B1E03D29

Q35005146-ACEE870D-330F-404E-B2FF-8E7D9512D97E

Q35005146-C4D4546C-4526-452C-9B9B-7BE0030A04A6

Q35005146-D2F4017A-96C0-43F1-B53B-B8670299E3F2

Q35005146-DD863140-7340-4C9C-AB30-760C37965A57

Q35005146-F6AFAE52-0995-485D-AA6E-B635B4DC161D

P2860

Q35005146-4037D182-D13E-4020-8B36-B036F34B82F8

Q35005146-43773996-60F8-4550-8C69-1BBAD5FD88DE

Q35005146-5DF9E495-304F-461A-972C-1F0AFB9803AB

Q35005146-5E958888-2956-4A56-89F2-306E97344A47

Q35005146-84174BCF-82A0-4680-9A88-2093AACBAC0F

Q35005146-85A9243C-37D7-43A3-BB76-68668A1491E1

Q35005146-8C825C15-837F-4CE0-A437-0E2961D8597F

Q35005146-9B302825-1DBF-48E8-87D4-E139664CFFF7

Q35005146-A1EF8516-10C6-4C65-853F-30D8C19DBBFD

Q35005146-A67C1140-9482-4150-AF7F-7CEED8A94E28

P304

Q35005146-DBCC14D8-BDCB-450B-8482-FFB799F1A488

P31

Q35005146-3BBB7813-13B8-42D3-9B26-0EFA6B61898A

P356

Q35005146-48DA6A5F-E915-4E3C-9C48-19F68A9B92BB

P407

Q35005146-911DC8E3-82F2-4572-ACCF-416A625F457D

P433

Q35005146-6610A1E1-5978-422E-91D4-D398215325BE

P478

Q35005146-C319DD32-A04E-4D31-B174-A34C3D4804EF

P50

Q35005146-5D36D8F4-63F3-426C-8683-90C162560FCD

Q35005146-A8E59C46-F499-4994-944D-3A44761D6047

Q35005146-F79E652B-231C-4256-8AC4-1DECD40BF849

P577

Q35005146-F45124E0-B982-4503-99F0-9981305DE52F

P698

Q35005146-819D40A1-9873-48A0-825E-0FC4803C9426

P932

Q35005146-5DE01555-26B5-45E7-8458-F237C16391E7

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Raltegravir concentrations in ...... aining regimen (DIVA 01 study)

@en

P2093

Anne-Geneviève Marcelin

http://www.w3.org/2001/XMLSchema#string

Catherine Crenn-Hebert

http://www.w3.org/2001/XMLSchema#string

Cathia Soulié

http://www.w3.org/2001/XMLSchema#string

Claudia Ferreira

http://www.w3.org/2001/XMLSchema#string

Cyril Clavel

http://www.w3.org/2001/XMLSchema#string

François Bissuel

http://www.w3.org/2001/XMLSchema#string

Houria Ichou

http://www.w3.org/2001/XMLSchema#string

Isabelle Heard

http://www.w3.org/2001/XMLSchema#string

Laurent Mandelbrot

http://www.w3.org/2001/XMLSchema#string

Roland Tubiana

http://www.w3.org/2001/XMLSchema#string

P2860

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy.

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.

HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.

Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

Effects of omeprazole on plasma levels of raltegravir.

P304

3018-3021

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01460-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Anne-Geneviève Marcelin

Christine Katlama

Gilles Peytavin

P577

2011-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21444705

http://www.w3.org/2001/XMLSchema#string

P932

3101453

http://www.w3.org/2001/XMLSchema#string